HIV/hepatitis C virus-coinfected patients with normal alanine aminotransferase levels

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 5, 2006, Pages 582-589

  Gonzalez, Stevan A ^a   Liu, Ruei Che ^b   Edlin, Brian R ^a   Jacobson, Ira M ^a   Talal, Andrew H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Columbia University ^*  (United States)

Author keywords

Hepatitis C virus; HIV HCV coinfection; Liver inflammation; Normal alanine aminotransferase

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ARTICLE; CHRONIC LIVER DISEASE; COMORBIDITY; DISEASE COURSE; ENZYME BLOOD LEVEL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CONTINENTAL POPULATION GROUPS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; REFERENCE VALUES; RISK FACTORS; VIRAL LOAD;

EID: 33646819027     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000214806.90841.c8     Document Type: Article

References (42)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
3. Kew MC. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet. 2000;355:591-592.
4. Adams PC, Arthur MJ, Boyer TD, et al. Screening in liver disease: report of an AASLD clinical workshop. Hepatology. 2004;39:1204-1212.
5. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691-1696.
6. Inglesby TV, Rai R, Astemborski J, et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology. 1999;29:590-596.
7. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology. 1998;27:868-872.
8. Jamal MM, Soni A, Quinn PG, et al. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology. 1999;30:1307-1311.
9. Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology. 2000;118:760-764.
10. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology. 2001;34:1000-1005.
11. Puoti C, Castellacci R, Montagnese F, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol. 2002;37:117-123.
12. Hui CK, Belaye T, Montegrande K, et al. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol. 2003;38:511-517.
13. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
14. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240-247.
15. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. 2002;100:1584-1589.
16. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302-1306.
17. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
18. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol. 1998;28:945-950.
19. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193-1199.
20. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis. 2001;183:134-137.
21. Serfaty L, Costagliola D, Wendum D, et al. Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study. AIDS. 2001;15:2011-2016.
22. Sterling RK, Contos MJ, Sanyal AJ, et al. The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr. 2003;32:30-37.
23. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372-374.
24. Okamoto H, Okada S, Sugiyama Y, et al. Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. J Gen Virol. 1991;72:2697-2704.
25. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 1994;19:1321-1324.
26. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993;74:2391-2399.
27. Stata Base Reference Manual. Release 8. College Station, TX: Stata Corp; 2003.
28. Eyster ME, Fried MW, Di Bisceglie AM, et al. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood. 1994;84:1020-1023.
29. Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis. 2004;38(suppl 2):S49-S55.
30. National Institutes of Health Consensus Development Conference statement: management of hepatitis C, June 10-12, 2002. Hepatology. 2002;36:S3-S20.
31. Fonquernie L, Serfaty L, Charrois A, et al. Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV-1-infected patients. HIV Med. 2004;5:385-390.
32. Cahen DL, van Leeuwen DJ, ten Kate FJ, et al. Do serum ALAT values reflect the inflammatory activity in the liver of patients with chronic viral hepatitis? Liver. 1996;16:105-109.
33. McCormick SE, Goodman ZD, Maydonovitch CL, et al. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol. 1996;91:1516-1522.
34. Toyoda H, Kumada T, Kiriyama S, et al. Influence of age, sex, and degree of liver fibrosis on the association between serum alanine aminotransferase levels and liver inflammation in patients with chronic hepatitis C. Dig Dis Sci. 2004;49:295-299.
35. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol. 2003;38(suppl 1):S38-S53.
36. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730-739.
37. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97-104.
38. Poynard T, Bedossa P, Opolon P. For the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825-832.
39. Benhamou Y, Bochet M, Di Martino V, et al. The Multivirc Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 1999;30:1054-1058.
40. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
41. EASL International Consensus Conference on hepatitis C, Paris, February 26-27, 1999. Consensus statement. J Hepatol. 1999;31 suppl 1:3-8.
42. Zeremski M, Talal AH. Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV coinfected patients? J Hepatol. 2005;43:2-5.